Scientific Reports · 2023 · 28 citations · 33 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryMulti-target Drug DesignOncology PharmacologyTyrosine Kinase InhibitorsMet InhibitorsMet Receptor Tyrosine KinaseMulti-target Tyrosine Kinase InhibitorsSorafenib TherapyTargeted Kinase InhibitionTyrosine Kinase Inhibitor TherapyTyrosine-targeted InhibitorsVegfr Inhibitors
Abstract Multitarget anticancer drugs are more superior than single target drugs regarding patient compliance, drug adverse effects, drug-drug interactions, drug resistance as well as pharmaceutical industry economics. Dysregulation of both VEGFR-2 and c-Met tyrosine kinases (TKs) could result in development and progression of different human cancers. Herein, we reported a novel series of 3-phenylquinazolin-2,4(1 H ,3 H )-diones with thiourea moiety as dual VEGFR-2/c-Met TKs. Compared to sorafenib, cabozantinib went behind VEGFR-2 inhibition to target c-Met TK. The dual VEGFR-2/c-Met inhibitory activity of cabozantinib is due to a longer HB domain than that of sorafenib. Based on pharmacophore of cabozantinib analogues, we designed new dual VEGFR-2/c-Met TKs. We synthesized the target compounds via a new single pot three-component reaction. The cytotoxic activity of synthesized compounds was conducted against HCT-116 colorectal cancer cell line. Compounds 3c and 3e exhibited the highest cytotoxic activity against HCT-116 cell line (IC 50 1.184 and 3.403 µM, respectively). The in vitro enzyme inhibitory activity was carried out against both VEGFR-2 and c-Met TKs. Compound 3e has the highest inhibitory activity against both VEGFR-2/c-Met (IC 50 = 83 and 48 nM, respectively). Docking studies showed that α-oxo moiety in quinazoline ring formed hydrogen bond HB with Met1160 residue in the adenine region of c-Met TK.
33
Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text
Gretchen M. Schroeder, Yongmi An, Zhen‐Wei Cai et al. · Journal of Medicinal Chemistry · 2009 · 277 citations · Full text
Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 77 citations
Medicine, Oncology, Pharmacology +17